Headlines about AbbVie (NYSE:ABBV) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AbbVie earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.9297749393087 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media stories that may have impacted Accern’s scoring:
Several brokerages have recently weighed in on ABBV. ValuEngine lowered shares of AbbVie from a “buy” rating to a “hold” rating in a research report on Friday. Piper Jaffray Companies lowered shares of AbbVie from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $125.86 to $66.62 in a research report on Friday, June 1st. Credit Suisse Group set a $89.00 price target on shares of AbbVie and gave the company a “sell” rating in a report on Wednesday, June 6th. BMO Capital Markets reissued a “sell” rating and set a $80.00 price target on shares of AbbVie in a report on Thursday, April 5th. Finally, Jefferies Financial Group set a $122.00 price target on shares of AbbVie and gave the company a “buy” rating in a report on Friday, April 13th. Four analysts have rated the stock with a sell rating, nine have given a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $106.51.
Shares of NYSE ABBV opened at $93.05 on Tuesday. AbbVie has a 1-year low of $69.38 and a 1-year high of $125.86. The stock has a market capitalization of $148.36 billion, a price-to-earnings ratio of 16.62, a P/E/G ratio of 0.87 and a beta of 1.61. The company has a quick ratio of 1.10, a current ratio of 1.20 and a debt-to-equity ratio of 8.70.
AbbVie (NYSE:ABBV) last announced its earnings results on Thursday, April 26th. The company reported $1.87 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.08. AbbVie had a net margin of 21.55% and a return on equity of 186.47%. The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.60 billion. During the same period in the previous year, the firm posted $1.28 earnings per share. The company’s revenue was up 21.4% on a year-over-year basis. equities research analysts anticipate that AbbVie will post 7.8 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, August 15th. Shareholders of record on Friday, July 13th will be paid a $0.96 dividend. This represents a $3.84 dividend on an annualized basis and a dividend yield of 4.13%. The ex-dividend date is Thursday, July 12th. AbbVie’s dividend payout ratio is presently 68.57%.
In related news, Director Edward J. Rapp bought 1,013 shares of the company’s stock in a transaction on Wednesday, June 20th. The stock was bought at an average cost of $98.63 per share, with a total value of $99,912.19. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Timothy J. Richmond sold 17,588 shares of the business’s stock in a transaction dated Friday, June 15th. The stock was sold at an average price of $99.47, for a total transaction of $1,749,478.36. The disclosure for this sale can be found here. Insiders own 0.07% of the company’s stock.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.